ImmunityBio, Inc. IBRX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$351.47M+15.0% | -$413.65M+29.2% | -$583.85M-39.9% | -$417.32M-19.3% | ||
| $15.53M-11.6% | $17.55M-5.2% | $18.51M+1.4% | $18.26M+28.2% | ||
| $36.81M+6.9% | $34.43M-30.0% | $49.16M+22.4% | $40.18M-29.7% | ||
| -$304.94M+22.1% | -$391.24M-6.7% | -$366.76M-8.7% | -$337.51M-23.0% | ||
| $3.85M-44.2% | $6.89M-77.5% | $30.58M-60.9% | $78.16M+133% | ||
| —— | —— | -$32.72M— | —— | ||
| —— | $0— | $0— | —— | ||
| —— | $0— | $0— | —— | ||
| $400.24M+42.1% | $281.63M-49.6% | $558.34M+139% | $233.61M-53.8% | ||
| —— | —— | $160.82M— | —— | ||
| -$308.78M+22.4% | -$398.12M-0.2% | -$397.34M+4.4% | -$415.67M-35.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does ImmunityBio, Inc. generate?
- ImmunityBio, Inc. (IBRX) generated -$294.4M in operating cash flow over the trailing twelve months.
- What is ImmunityBio, Inc.'s free cash flow?
- After $4.5M of capital expenditures, ImmunityBio, Inc.'s free cash flow was -$298.9M over the trailing twelve months, up 20.7% year over year.
- Where does ImmunityBio, Inc.'s cash flow data come from?
- Every line is extracted from ImmunityBio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
